Tetrous announced the issuance of U.S. Patent No. 11,660,373, related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RC, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is currently available in the United States and Australia.
EnFix RC is designed to enhance healing at the tendon-to-bone interface, for example at the enthesis, where failure often occurs. The 100% demineralized bone fiber implants provide osteoinductivity and osteoconductivity in a graft, while FormLok technology imparts shape retention to the device, even when immersed in liquid, as is often required for use in arthroscopic surgery. The implant has minimal disruption to the existing surgical technique.
“We are excited to introduce EnFix RC. We flip the script by concentrating on enthesis repair, an unmet need in rotator cuff surgery,” said Andy Carter, Ph.D., Tetrous’ Co-Founder and Director and co-inventor on the issued patent. “The issue of this new patent further enhances our strong portfolio of intellectual property and demonstrates our ongoing commitment to innovation and leadership in sports medicine.”
Tetrous announced the issuance of U.S. Patent No. 11,660,373, related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RC, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is currently available in the United States and Australia.
EnFix...
Tetrous announced the issuance of U.S. Patent No. 11,660,373, related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RC, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is currently available in the United States and Australia.
EnFix RC is designed to enhance healing at the tendon-to-bone interface, for example at the enthesis, where failure often occurs. The 100% demineralized bone fiber implants provide osteoinductivity and osteoconductivity in a graft, while FormLok technology imparts shape retention to the device, even when immersed in liquid, as is often required for use in arthroscopic surgery. The implant has minimal disruption to the existing surgical technique.
“We are excited to introduce EnFix RC. We flip the script by concentrating on enthesis repair, an unmet need in rotator cuff surgery,” said Andy Carter, Ph.D., Tetrous’ Co-Founder and Director and co-inventor on the issued patent. “The issue of this new patent further enhances our strong portfolio of intellectual property and demonstrates our ongoing commitment to innovation and leadership in sports medicine.”
Copy to clipboard 
